menu
    • menu
    [{"orgOrder":0,"company":"Arctic Vision","sponsor":"Loyal Valley Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.10000000000000001,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Loyal Valley Capital","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Loyal Valley Capital"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"ActualEyes","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Rho-associated kinase-Human corneal endothelial cells","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Arctic Vision","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Arctic Vision \/ Arctic Vision","highestDevelopmentStatusID":"4","companyTruncated":"Arctic Vision \/ Arctic Vision"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"University of Hong Kong","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"ARVN601","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Arctic Vision \/ University of Hong Kong","highestDevelopmentStatusID":"4","companyTruncated":"Arctic Vision \/ University of Hong Kong"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Arctic Vision","highestDevelopmentStatusID":"12","companyTruncated":"Arctic Vision \/ Arctic Vision"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Eyenovia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Arctic Vision \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Eyenovia"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Eyenovia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Arctic Vision \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Eyenovia"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"12","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"14","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Triamcinolone Acetonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"14","companyTruncated":"Arctic Vision \/ Clearside Biomedical"}]

    Find Clinical Drug Pipeline Developments & Deals by Arctic Vision

    Menu

    Arctic Vision

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Clearside Biomedical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Clearside & Arctic Vision Partner with Santen for ARVN001 in Uveitic Macular Edema

                            Details : Under the agreement, Arctic Vision has granted the rights of Arcatus (triamcinolone acetonide injectable suspension) to Santen to commercialize in China for macular edema associated with uveitis.

                            Brand Name : Arcatus

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 07, 2024

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Clearside Biomedical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Clearside Biomedical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clearside Biomedical’s Partner Reports Positive Phase 3 Results for ARCATUS® in China

                            Details : Arcatus is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis.

                            Brand Name : Arcatus

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 29, 2024

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Clearside Biomedical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Clearside Biomedical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug ...

                            Details : Arcatus is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis and is referred as Xipere, approved in United States.

                            Brand Name : Arcatus

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 10, 2023

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Clearside Biomedical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Eyenovia

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLi...

                            Details : ARVN003 (pilocarpine microdose ophthalmic solution/Microline), a proprietary formulation based on microdosing platform Optejet® for the pharmacologic treatment for presbyopia.

                            Brand Name : MicroLine

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 06, 2022

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Eyenovia

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Clearside Biomedical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand,...

                            Details : XIPERE, referred to as ARVN001 by Arctic Vision, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS®) using Clearside’s patented SCS Microinjector®.

                            Brand Name : Xipere

                            Molecule Type : Small molecule

                            Upfront Cash : $3.0 million

                            September 09, 2021

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Clearside Biomedical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Eyenovia

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            China NMPA Clears Arctic Vision’s IND Application for Phase III study of ARVN003 to Treat Presbyopia

                            Details : ARVN003 is a pharmacologic treatment for presbyopia. The product is developed based on Optejet, a proprietary micro-dosing administration device utilizing MAP technology, and pilocapine, the well-established ophthalmic medicine for temporary improvement ...

                            Brand Name : MicroLine

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 03, 2021

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Eyenovia

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Clearside Biomedical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Arctic Vision Expands License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include Asean Co...

                            Details : ARVN001 is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS®) through Clearside’s patented SCS Microinjector®.

                            Brand Name : Xipere

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 15, 2021

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Clearside Biomedical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARVN601

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : University of Hong Kong

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arctic Vision Joins Forces with the University of Hong Kong to Discover and Develop Novel Neuroprotective Ther...

                            Details : ARVN601 Neuroprotection, in the form of non-IOP-related interventions to prevent or delay glaucomatous neurodegeneration, has been underscored to be an unmet need in the management of glaucoma ever since the 2010 World Glaucoma Association Consensus Meet...

                            Brand Name : ARVN601

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 05, 2021

                            Lead Product(s) : ARVN601

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : University of Hong Kong

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rho-associated kinase-Human corneal endothelial cells

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Recipient : ActualEyes

                            Deal Size : $35.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Arctic Vision Announces Exclusive Licensing Agreement With ActualEyes to Develop and Commercialize Cell Therap...

                            Details : Arctic Vision will develop and market ActualEyes’ AE-101, for the treatment of corneal endothelial dysfunction in Greater China and South Korea. ARVN901 (AE-101) is a novel cell-injection therapy developed using cultured hCECs combined with a ROCK inhi...

                            Brand Name : AE101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 14, 2021

                            Lead Product(s) : Rho-associated kinase-Human corneal endothelial cells

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Recipient : ActualEyes

                            Deal Size : $35.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arctic Vision

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Loyal Valley Capital

                            Deal Size : $100.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion

                            Details : Arctic Vision currently has three late-stage in-licensed products: ARVN001 for uveitic macular edema (UME), ARVN002 for pediatric progressive myopia and ARVN003 for presbyopia.

                            Brand Name : ARVN001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 10, 2021

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Loyal Valley Capital

                            Deal Size : $100.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth